2024
DOI: 10.1007/s00277-024-05892-9
|View full text |Cite
|
Sign up to set email alerts
|

The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience

Yi Dai,
Lin Luo,
Zhenbin Wei
et al.

Abstract: Relapsed/refractory acute leukemia (R/R-AL) is associated with a low remission rate, short survival rate, and poor prognosis. Treating R/R-AL remains challenging as there is no standardized effective regimen; hence, there is a need for efficient therapies. CD38 expression has been observed in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Daratumumab is a humanized anti-CD38 monoclonal antibody used to treat multiple myeloma and has been reported to treat R/R-AL safely and effectively. Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 27 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?